openPR Logo
Press release

2017 Report: Hypertrophic Cardiomyopathy Industry Pipeline Review, H1 Analysis

05-22-2017 08:46 AM CET | Health & Medicine

Press release from: Orbis Research

Orbis Research

Orbis Research

Orbisreserach.Com Adds “H1 Hypertrophic Cardiomyopathy Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database

Hypertrophic Cardiomyopathy - Pipeline Review, H1 2017, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/289264 .

Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Browse the full report @ http://www.orbisresearch.com/reports/index/hypertrophic-cardiomyopathy-pipeline-review-h1-2017 .

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/289264 .

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Gilead Sciences Inc
Heart Metabolics Ltd
Lead Discovery Center GmbH
MyoKardia Inc

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact sales@orbisresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 2017 Report: Hypertrophic Cardiomyopathy Industry Pipeline Review, H1 Analysis here

News-ID: 545053 • Views:

More Releases from Orbis Research

Blood Purification Devices Market 2023-2028 | Top Players Baxter International, Cerus Corporation, Cytosorbents Corporation, Nikkiso Co.Ltd, Asahi Kasei Corporation, Aethlon Medical, Haemonetics, Jafron, B. Braun, Fresenius
Blood Purification Devices Market 2023-2028 | Top Players Baxter International, …
Based on the type segment, the portable equipment segment is expected to hold the largest share in Blood Purification Devices in the year 2028. Professionals that are actively involved in the ongoing purification of blood tend to favour portable equipment. Equipment that is portable enables effective emergency care. Additionally, portable equipment is rather space-efficient and compact, which promotes widespread use throughout the blood-purification process. In a manner similar to how
Clean Beauty Market to Grow at 40.1% CAGR by 2028 - Key Players are Bare Minerals, The Honest Company, Fenty Beauty, Aveda Corporation, Westman Atelier, Victoria Beckham Beauty, Kora Organics, Saie, and True Botanicals
Clean Beauty Market to Grow at 40.1% CAGR by 2028 - Key Players are Bare Mineral …
Clean beauty is described as beauty and personal care products that are made with the safest possible ingredients and have the lowest possible environmental impacts. Clean beauty pertains to products that are safe, non-toxic, and clearly labelled ingredients Also, the ingredients used are cruelty-free and are screened for non-GMO feedstock and residual pesticides. Request a pdf brochure @ https://www.orbisresearch.com/contacts/request-sample/6941781 The Clean Beauty Market is valued at USD 5163.17 Million in 2021 and
Outdoor Power Equipment Market Worth USD 6.49 Bn by 2027 - Industry Trends and S …
The outdoor power equipment generally includes, brush cutters, edger, chain saws, power rakes, and more. Outdoor power equipment is commonly used by end users, such as lawn & plant care providers and landscape service providers, for commercial purposes. The global outdoor power equipment market in 2021 was valued at US$32.22 billion. The market value is projected to reach US$46.49 billion by 2027. Outdoor power equipment (OPE) is an equipment with small
Merchant API Market to reach US$119.11 billion by 2027 - Industry Trends, Growth Drivers, Key Companies and Future Opprtunities
Merchant API Market to reach US$119.11 billion by 2027 - Industry Trends, Growth …
The latest research on "Global Merchant API Market: Analysis By Molecular Type, By Segment, By Type, By Type of Synthesis, By End-User, By Region Size And Trends With Impact Of COVID-19 And Forecast up to 2027" have been added to OrbisResearch.com store. The merchant API market refers to the use of APIs by merchants, or businesses that sell goods and services, to connect their systems and processes with those of other

All 5 Releases


More Releases for Hypertrophic

Rising Obesity Rates Fuel Growth In Hypertrophic Cardiomyopathy Treatment Market …
The Hypertrophic Cardiomyopathy Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Hypertrophic Cardiomyopathy Treatment Market Size and Projected Growth Rate? The market size of treatment for hypertrophic cardiomyopathy has seen consistent growth in recent times. The size is projected to increase from
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate? In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate? In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its
Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate? The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines. The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is
Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate? The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines. The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is
Hypertrophic Cardiomyopathy Market - Empowering Lives, Elevating Heart Health: H …
Newark, New Castle, USA: The "Hypertrophic Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Hypertrophic Cardiomyopathy Market: https://www.growthplusreports.com/report/hypertrophic-cardiomyopathy-market/8833 This latest report researches the industry structure, sales, revenue,